IP Library Granted Patent US 11,014,962
Granted Patent B2
US 11,014,962 · App. 16/089,443 · Granted May 25, 2021

Method for protein purification

Inventors: Richard Jones (Slough, GB); Jonathan Symmons (Slough, GB); Saskia Hocking (Slough, GB)
Assignee: UCB BIOPHARMA SRL
C07K1/22B01D15/1871B01D15/265B01D15/362B01D15/363B01D15/3809B01J20/20B01J20/282B01J47/014C07K1/18C07K1/20C07K1/34C07K16/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,014,962
App. No.
16/089,443
Granted
May 25, 2021
Kind
B2
Abstract

The present invention provides a method for manufacturing antibodies or a fragment thereof with reduced levels of antibody reduction related impurities.

Claims (26)

1. A method for manufacturing an antibody or fragment thereof comprising:

expressing said antibody or fragment thereof in a host cell;

recovering a mixture containing the antibody or fragment thereof, host cell debris, and impurities; and

purifying said antibody or fragment thereof from the mixture wherein said purification comprises:

activated carbon filtration, followed by

protein A chromatography.

2. The method according to claim 1 , wherein said purification comprises at least one further chromatography step.

3. The method according to claim 2 , wherein said further chromatography steps comprise cation exchange chromatography and/or anion exchange chromatography.

4. The method according to claim 1 , wherein the recovered antibody or fragment thereof comprises native disulfide bonds.

5. The method according to claim 1 , wherein the recovered antibody or fragment thereof comprises native inter-chain disulfide bonds.

6. The method according to claim 1 , wherein said host cell is a mammalian host cell and the mixture containing the antibody is the cell culture supernatant.

7. The method according to claim 6 , wherein said purification process additionally comprises depth filtration of the cell culture supernatant prior to activated carbon filtration.

8. The method according to claim 2 , wherein depth filtration and activated carbon filtration are operated in-line.

9. The method according to claim 1 , wherein the antibody or fragment recovered from the protein A chromatography comprises less than 10%, less than 5%, less than 4%, less than 3%, less than 2% or less than 1% antibody reduction related impurities.

10. The method according to claim 1 , wherein the antibody or fragment recovered from the protein A chromatography comprises less antibody reduction related impurities than the antibody or fragment recovered from the same process without an activated carbon filtration step.

11. A method for the prevention of disulfide bond reduction during purification of an antibody or fragment thereof expressed in a host cell comprising:

activated carbon filtration step, followed by

protein A chromatography.

12. A method for purifying an antibody or fragment thereof from a liquid mixture containing contaminants comprising:

filtering said liquid mixture with an activated carbon filter, followed by

protein A chromatography.

13. The method according to claim 12 , wherein said recovered antibody or fragment thereof comprises native disulfide bonds.

14. The method according to claim 13 , wherein the recovered protein comprises native inter-chain disulfide bonds.

15. A method for decreasing the amount of reducing agents during purification of an antibody or antibody fragment thereof comprising:

activated carbon filtration, followed by

protein A chromatography.

Assignments (4)
CHANGE OF NAME Recorded Apr 15, 2021
From: UCB BIOPHARMA SPRL
To: UCB BIOPHARMA SRL
Reel/Frame 055949/0488 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 12, 2018
From: CELLTECH R&D LIMITED
To: UCB BIOPHARMA SPRL
Reel/Frame 047754/0980 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 12, 2018
From: CELLTECH R&D LIMITED
To: UCB BIOPHARMA SPRL
Reel/Frame 047755/0059 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 12, 2018
From: JONES, RICHARD; SYMMONS, JONATHAN; HOCKING, SASKIA
To: CELLTECH R&D LIMITED
Reel/Frame 047791/0365 →
Priority Claims (1)
GB 1605562 · Apr 1, 2016 · national
Continuity (1)
Related Publication 20190153028A1 · May 23, 2019